drugset
Drugs / MK0557
last change Oct 2008 re-read 3 minutes ago

MK0557

Small molecule targets NPY5R via inhibition

Developed for
obesity disorder · paranoid schizophrenia
Investigated by
Merck Sharp & Dohme LLC

Trials 5

today NCT00482430 · Ph 2 NCT00533481 · Ph 2 NCT00092872 · Ph 3 NCT00092859 · Ph 3 NCT00533598 · Ph 2
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 23 trials
Phase 2 NCT00482430 Sep 2007 → Oct 2008 paranoid schizophrenia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 2 NCT00533481 Feb → Dec 2004 obesity disorder Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 2 NCT00533598 Sep 2002 → Jun 2003 obesity disorder Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 32 trials · 1 met primary
Phase 3 NCT00092872 Nov 2003 → Feb 2005 obesity disorder Merck Sharp & Dohme LLC Completed Met primary
Phase 3 NCT00092859 Aug 2003 → Jun 2005 obesity disorder Merck Sharp & Dohme LLC Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as MK-0557 “We tested the hypothesis that blockade of the NPY5R will lead to weight loss in humans using MK-0557, a potent, highly selective, orally active NPY5R antagonist.” PMID 17011500 ↗ Oct 2006
5

NCT00092859 ↗

NCT00533598 ↗

NCT00482430 ↗

NCT00533481 ↗

NCT00092872 ↗
Action Inhibit “blockade of the NPY5R will lead to weight loss” PMID 17011500 ↗ Oct 2006
Modality Small molecule — CHEMBL595573 ↗
Route Oral “orally active NPY5R antagonist” PMID 17011500 ↗ Oct 2006
Target NPY5R “blockade of the NPY5R will lead to weight loss” PMID 17011500 ↗ Oct 2006